Form 4: Cargo Therapeutics Director Jane Henderson Reports Stock Option Grants

Director Jane Henderson reports the acquisition of stock options in Cargo Therapeutics, Inc.

Summary

• Jane Henderson, a director of CARGO Therapeutics, Inc., filed a Form 4 with the SEC.
• The filing reports the grant of two stock option tranches on June 4, 2024.
• The first tranche is for 19,785 shares, vesting fully on the earlier of June 4, 2025, or the next Annual Meeting following June 4, 2024.
• The second tranche is for 39,402 shares, vesting monthly over three years from June 4, 2024.
• The exercise price for both options is $19.17 per share.
• Following the transaction, Henderson directly owns options for 59,187 shares.

Sentiment

Score: 6

Explanation: The document is a routine filing related to stock option grants, which is generally neutral. It indicates alignment of director interests with shareholders.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders.
• The vesting schedule incentivizes continued service to the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• Vesting schedules, such as the one described in the filing, are typical for incentivizing long-term commitment and performance.
• The specific number of shares granted and the exercise price would need to be compared to similar companies in the biotech industry to assess the competitiveness and appropriateness of the grant.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates